A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor–dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor–dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2
Authors
Keywords
Adjuvant, Dendritic cell, Dendritoma, Melanoma, Vaccine
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 65, Issue 4, Pages 383-392
Publisher
Springer Nature
Online
2016-02-19
DOI
10.1007/s00262-016-1809-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
- (2015) Kathleen M. Mahoney et al. CLINICAL THERAPEUTICS
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical testing of a novel personalized cancer vaccine for all solid tumors and all patients
- (2015) Doreen Jackson et al. Journal for ImmunoTherapy of Cancer
- Update on Vaccines for High-Risk Melanoma
- (2014) Sarah A. Weiss et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Immune Checkpoint Blockade
- (2014) Jarushka Naidoo et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Novel dendritic cell-based vaccination in late stage melanoma
- (2014) Erika J Schneble et al. Human Vaccines & Immunotherapeutics
- Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)
- (2013) D. McDermott et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
- (2013) P. A. Ott et al. CLINICAL CANCER RESEARCH
- Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
- (2013) Wim H.J. Kruit et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial
- (2013) Alexander M.M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection
- (2012) Andrzej Mackiewicz et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients
- (2012) Sergiusz Markowicz et al. MEDICAL ONCOLOGY
- Vaccines for Melanoma and Renal Cell Carcinoma
- (2012) Howard L. Kaufman SEMINARS IN ONCOLOGY
- Melanoma vaccines: developments over the past 10 years
- (2011) Oliver Klein et al. Expert Review of Vaccines
- Does metastasectomy improve survival in patients with stage IV melanoma? a cancer registry analysis of outcomes
- (2011) Nabil Wasif et al. JOURNAL OF SURGICAL ONCOLOGY
- Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine
- (2011) Matthew S. Block et al. MELANOMA RESEARCH
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial
- (2009) C. L. Slingluff et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More